Adenosine and glutamate extracellular concentrations and mitogen-activated protein kinases in the striatum of Huntington transgenic mice. Selective antagonism of adenosine A2A receptors reduces transmitter outflow

[1]  Rafael Franco,et al.  A1 Adenosine Receptors Accumulate in Neurodegenerative Structures in Alzheimer's Disease and Mediate Both Amyloid Precursor Protein Processing and Tau Phosphorylation and Translocation , 2003, Brain pathology.

[2]  L. Ellerby,et al.  Kennedy's Disease , 2003, Journal of Biological Chemistry.

[3]  F. Pedata,et al.  Adenosine A2A antagonism increases striatal glutamate outflow in the quinolinic acid rat model of Huntington’s disease , 2003, Brain Research.

[4]  S. Schiffmann,et al.  A Dual Role of Adenosine A2A Receptors in 3-Nitropropionic Acid-Induced Striatal Lesions: Implications for the Neuroprotective Potential of A2A Antagonists , 2003, The Journal of Neuroscience.

[5]  R. Jackisch,et al.  Mice transgenic for exon 1 of Huntington's disease: properties of cholinergic and dopaminergic pre‐synaptic function in the striatum , 2003, Journal of neurochemistry.

[6]  F. Pedata,et al.  Adenosine A2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats. , 2003, European journal of pharmacology.

[7]  M. MacDonald,et al.  Specific progressive cAMP reduction implicates energy deficit in presymptomatic Huntington's disease knock-in mice. , 2003, Human molecular genetics.

[8]  G. Deuschl,et al.  Activation of microglia by human neuromelanin is NF‐κB‐dependent and involves p38 mitogen‐activated protein kinase: implications for Parkinson's disease , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[9]  F. Pedata,et al.  The selective A2A receptor antagonist SCH 58261 reduces striatal transmitter outflow, turning behavior and ischemic brain damage induced by permanent focal ischemia in the rat , 2003, Brain Research.

[10]  T. Burton,et al.  Anti-apoptotic wild-type Alzheimer amyloid precursor protein signaling involves the p38 mitogen-activated protein kinase/MEF2 pathway. , 2002, Brain research. Molecular brain research.

[11]  D. Bozyczko‐Coyne,et al.  Protein Tyrosine Phosphatases Are Up-regulated and Participate in Cell Death Induced by Polyglutamine Expansion* , 2002, Journal of Biological Chemistry.

[12]  M. Giovannini,et al.  β-Amyloid-Induced Inflammation and Cholinergic Hypofunction in the Rat Brain in Vivo: Involvement of the p38MAPK Pathway , 2002, Neurobiology of Disease.

[13]  H. Ichijo,et al.  Neuronal p38 MAPK signalling: an emerging regulator of cell fate and function in the nervous system , 2002, Genes to cells : devoted to molecular & cellular mechanisms.

[14]  D. Rigamonti,et al.  Calcium-dependent Cleavage of Endogenous Wild-type Huntingtin in Primary Cortical Neurons* , 2002, The Journal of Biological Chemistry.

[15]  Blair R. Leavitt,et al.  Caspase Cleavage of Mutant Huntingtin Precedes Neurodegeneration in Huntington's Disease , 2002, The Journal of Neuroscience.

[16]  C. Hsieh,et al.  The effect of aging on p38 signaling pathway activity in the mouse liver and in response to ROS generated by 3-nitropropionic acid , 2002, Mechanisms of Ageing and Development.

[17]  S. Schiffmann,et al.  Striatal and Cortical Neurochemical Changes Induced by Chronic Metabolic Compromise in the 3-Nitropropionic Model of Huntington's Disease , 2002, Neurobiology of Disease.

[18]  P. Calabresi,et al.  Mutant huntingtin goes straight to the heart , 2002, Nature Neuroscience.

[19]  K. Lindenberg,et al.  Impaired glutamate transport and glutamate-glutamine cycling: downstream effects of the Huntington mutation. , 2002, Brain : a journal of neurology.

[20]  James R. Burke,et al.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines , 2002, Nature Neuroscience.

[21]  N. Chandel,et al.  Mitochondrial ROS initiate phosphorylation of p38 MAP kinase during hypoxia in cardiomyocytes. , 2002, American journal of physiology. Lung cellular and molecular physiology.

[22]  D. Rubinsztein,et al.  Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin. , 2002, Human molecular genetics.

[23]  L. Raymond,et al.  Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease , 2002, Neuron.

[24]  M. Falchi,et al.  Blockade of Striatal Adenosine A2A Receptor Reduces, through a Presynaptic Mechanism, Quinolinic Acid-Induced Excitotoxicity: Possible Relevance to Neuroprotective Interventions in Neurodegenerative Diseases of the Striatum , 2002, The Journal of Neuroscience.

[25]  R. Friedlander,et al.  Caspases in Huntington’s Disease , 2001, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[26]  M. Gorospe,et al.  Transcriptional Induction of MKP-1 in Response to Stress Is Associated with Histone H3 Phosphorylation-Acetylation , 2001, Molecular and Cellular Biology.

[27]  K. Seta,et al.  Hypoxia-induced Regulation of MAPK Phosphatase-1 as Identified by Subtractive Suppression Hybridization and cDNA Microarray Analysis* , 2001, The Journal of Biological Chemistry.

[28]  Blair R. Leavitt,et al.  Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease , 2001, Science.

[29]  S. Latini,et al.  Adenosine Extracellular Brain Concentrations and Role of A2A Receptors in Ischemia , 2001, Annals of the New York Academy of Sciences.

[30]  K. Varani,et al.  The FASEB Journal express article 10.1096/fj.00-0730fje. Published online March 5, 2001. Aberrant amplification of A2A receptor signaling in striatal cells expressing mutant huntingtin , 2022 .

[31]  J. Linden,et al.  Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum , 2001, The Journal of comparative neurology.

[32]  S. Kassis,et al.  Inhibition of p38 mitogen‐activated protein kinase provides neuroprotection in cerebral focal ischemia , 2001, Medicinal research reviews.

[33]  A. J. Robinson,et al.  Regulation of p42/p44 MAPK and p38 MAPK by the adenosine A(1) receptor in DDT(1)MF-2 cells. , 2001, European journal of pharmacology.

[34]  O. Hansson,et al.  Altered striatal amino acid neurotransmitter release monitored using microdialysis in R6/1 Huntington transgenic mice , 2001, The European journal of neuroscience.

[35]  B. Fredholm,et al.  Human adenosine A(1), A(2A), A(2B), and A(3) receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2. , 2000, Molecular pharmacology.

[36]  F. Pedata,et al.  Striatal A2A adenosine receptor antagonism differentially modifies striatal glutamate outflow in vivo in young and aged rats , 2000, Neuroreport.

[37]  S. W. Davies,et al.  Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[38]  M. Beal.  Energetics in the pathogenesis of neurodegenerative diseases , 2000, Trends in Neurosciences.

[39]  A. Reith,et al.  Differential activation of MAPK/ERK and p38/SAPK in neurones and glia following focal cerebral ischaemia in the rat. , 2000, Brain research. Molecular brain research.

[40]  F. Pedata,et al.  Striatal outflow of adenosine, excitatory amino acids, gamma-aminobutyric acid, and taurine in awake freely moving rats after middle cerebral artery occlusion: correlations with neurological deficit and histopathological damage. , 1999, Stroke.

[41]  M. Beal,et al.  Bioenergetics in Huntington's Disease , 1999, Annals of the New York Academy of Sciences.

[42]  S. Snyder,et al.  Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization , 1999, Nature Medicine.

[43]  M. Freissmuth,et al.  Activation of Mitogen-activated Protein Kinase by the A2A-adenosine Receptor via a rap1-dependent and via a p21 ras -dependent Pathway* , 1999, The Journal of Biological Chemistry.

[44]  J. Woodgett,et al.  The stress-activated protein kinase pathways , 1999, Cellular and Molecular Life Sciences CMLS.

[45]  S. W. Davies,et al.  Altered neurotransmitter receptor expression in transgenic mouse models of Huntington's disease. , 1999, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[46]  K. Jacobson,et al.  Adenosine-induced cell death: evidence for receptor-mediated signalling , 1999, Apoptosis.

[47]  J. Penney,et al.  Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease , 1999, Nature.

[48]  S. W. Davies,et al.  Brain Neurotransmitter Deficits in Mice Transgenic for the Huntington’s Disease Mutation , 1999, Journal of neurochemistry.

[49]  I. Biaggioni,et al.  Role of p38 mitogen-activated protein kinase and extracellular signal-regulated protein kinase kinase in adenosine A2B receptor-mediated interleukin-8 production in human mast cells. , 1999, Molecular pharmacology.

[50]  F. Pedata,et al.  Striatal A2A adenosine receptors differentially regulate spontaneous and K+-evoked glutamate release in vivo in young and aged rats. , 1999, Neuroreport.

[51]  Taosheng Chen,et al.  A2B Adenosine and P2Y2 Receptors Stimulate Mitogen-activated Protein Kinase in Human Embryonic Kidney-293 Cells , 1999, The Journal of Biological Chemistry.

[52]  L. Bianchi,et al.  Simultaneous determination of basal and evoked output levels of aspartate, glutamate, taurine and 4-aminobutyric acid during microdialysis and from superfused brain slices. , 1999, Journal of chromatography. B, Biomedical sciences and applications.

[53]  J. Penney,et al.  Axonal transport of N-terminal huntingtin suggests early pathology of corticostriatal projections in Huntington disease. , 1999, Journal of neuropathology and experimental neurology.

[54]  S. Tabrizi,et al.  Biochemical abnormalities and excitotoxicity in Huntington's disease brain , 1999, Annals of neurology.

[55]  E. Ongini,et al.  Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats , 1998, Neuroreport.

[56]  O. Vitolo,et al.  Adenosine and ADP prevent apoptosis in cultured rat cerebellar granule cells , 1998, Brain Research.

[57]  S. Vincent,et al.  Neurotransmitter regulation of MAP kinase signaling in striatal neurons in primary culture , 1998, Synapse.

[58]  S. W. Davies,et al.  Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions? , 1998, The Lancet.

[59]  H. Haas,et al.  Adenosine A1 receptor-mediated depression of corticostriatal and thalamostriatal glutamatergic synaptic potentials in vitro , 1997, Brain Research.

[60]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[61]  K. Gołembiowska,et al.  Adenosine receptors--the role in modulation of dopamine and glutamate release in the rat striatum. , 1997, Polish journal of pharmacology.

[62]  B. Fredholm,et al.  Down-regulation of adenosine A2A receptors upon NGF-induced differentiation of PC12 cells , 1997, Neuropharmacology.

[63]  K. Heidenreich,et al.  Apoptosis Induced by Withdrawal of Trophic Factors Is Mediated by p38 Mitogen-activated Protein Kinase* , 1997, The Journal of Biological Chemistry.

[64]  Mark Turmaine,et al.  Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation , 1997, Cell.

[65]  P. Calabresi,et al.  Endogenous Adenosine Mediates the Presynaptic Inhibition Induced by Aglycemia at Corticostriatal Synapses , 1997, The Journal of Neuroscience.

[66]  F. Pedata,et al.  In Vivo Amino Acid Release From the Striatum of Aging Rats: Adenosine Modulation , 1997, Neurobiology of Aging.

[67]  V. Sexl,et al.  Stimulation of the Mitogen-activated Protein Kinase via the A2A-Adenosine Receptor in Primary Human Endothelial Cells* , 1997, The Journal of Biological Chemistry.

[68]  C. Kuo,et al.  Fas activation of the p38 mitogen-activated protein kinase signalling pathway requires ICE/CED-3 family proteases , 1997, Molecular and cellular biology.

[69]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[70]  S. Augood,et al.  Reduction in enkephalin and substance P messenger RNA in the striatum of early grade Huntington's disease: A detailed cellularin situ hybridization study , 1996, Neuroscience.

[71]  Motonao Nakamura,et al.  Functional coupling of adenosine A2a receptor to inhibition of the mitogen-activated protein kinase cascade in Chinese hamster ovary cells. , 1996, The Biochemical journal.

[72]  K. Jacobson,et al.  Cerebral ischemia in gerbils: effects of acute and chronic treatment with adenosine A2A receptor agonist and antagonist. , 1995, European journal of pharmacology.

[73]  P. Popoli,et al.  Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats. , 1995, European journal of pharmacology.

[74]  Michael E. Greenberg,et al.  Opposing Effects of ERK and JNK-p38 MAP Kinases on Apoptosis , 1995, Science.

[75]  C A Ross,et al.  When more is less: Pathogenesis of glutamine repeat neurodegenerative diseases , 1995, Neuron.

[76]  S. Iversen.  Interactions between excitatory amino acids and dopamine systems in the forebrain: implications for schizophrenia and Parkinson's disease. , 1995, Behavioural pharmacology.

[77]  R. Nicoll,et al.  Release of adenosine by activation of NMDA receptors in the hippocampus. , 1994, Science.

[78]  F. Pedata,et al.  Effect of K+ depolarization, tetrodotoxin, and NMDA receptor inhibition on extracellular adenosine levels in rat striatum. , 1993, European journal of pharmacology.

[79]  S. Schiffmann,et al.  Striatal Restricted Adenosine A2 Receptor (RDC8) Is Expressed by Enkephalin but Not by Substance P Neurons: An In Situ Hybridization Histochemistry Study , 1991, Journal of neurochemistry.

[80]  B. Schleiffenbaum,et al.  Brain GABA levels in asymptomatic Huntington's disease. , 1990 .

[81]  F. Pedata,et al.  Cholinergic and noradrenergic denervations decrease labelled purine release from electrically stimulated rat cortical slices , 1989, Neuroscience.

[82]  M. Williams,et al.  Direct autoradiographic localization of adenosine A2 receptors in the rat brain using the A2-selective agonist, [3H]CGS 21680. , 1989, European journal of pharmacology.

[83]  J. Vonsattel,et al.  Morphometric Demonstration of Atrophic Changes in the Cerebral Cortex, White Matter, and Neostriatum in Huntington's Disease , 1988, Journal of neuropathology and experimental neurology.

[84]  J. Penney,et al.  Differential loss of striatal projection neurons in Huntington disease. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[85]  M. Beal,et al.  Amino acid neurotransmitter abnormalities in Huntington's disease and the quinolinic acid animal model of Huntington's disease. , 1987, Brain : a journal of neurology.

[86]  Joseph B. Martin,et al.  Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid , 1986, Nature.

[87]  R. Ferrante,et al.  Neuropathological Classification of Huntington's Disease , 1985, Journal of neuropathology and experimental neurology.

[88]  N. Neff,et al.  Location of adenosine release and adenosine A2 receptors to rat striatal neurons. , 1983, Life sciences.

[89]  I. Ferrer,et al.  Active, phosphorylation-dependent mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and Dementia with Lewy bodies , 2001, Journal of Neural Transmission.

[90]  Jiahuai Han,et al.  The p38 signal transduction pathway: activation and function. , 2000, Cellular signalling.

[91]  J. Neary,et al.  Trophic actions of extracellular ATP on astrocytes, synergistic interactions with fibroblast growth factors and underlying signal transduction mechanisms. , 1996, Ciba Foundation symposium.

[92]  B. Fredholm.  Chapter 11 Adenosine and Neuroprotection , 1996 .

[93]  J. Phillis,et al.  CGS 15943, an adenosine A2 receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil. , 1994, Life sciences.